

(12) UK Patent Application (19) GB (11) 2 233 451 (13) A  
(43) Date of A publication 09.01.1991

(21) Application No 8914749.0

(22) Date of filing 27.06.1989

(71) Applicant  
Tropix Inc

(Incorporated in the USA - Massachusetts)

17, Wiggins Avenue, Bedford, MA 01730,  
United States of America

(72) Inventors  
John C Voyta  
Edward Brooks  
Irene Bronstein

(74) Agent and/or Address for Service  
J A Kemp and Co  
14 South Square, Gray's Inn, London, WC1R 5LX,  
United Kingdom

(51) INT CL<sup>8</sup>  
G01N 21/76 33/53

(52) UK CL (Edition K)  
G1B BAH BBV B122 B622 B632  
U1S S1296

(56) Documents cited  
GB 2205945 A GB 2196118 A GB 2165354 A  
GB 2063469 A EP 0219352 A2 EP 0210449 A2  
EP 0175577 A EP 0046563 A  
Anal. Biochem. (1985)15(1) pp205-209 Matthews et al.  
Clin. Chem. (1984)30(5) pp653-657 Messeri et al.

(58) Field of search  
UK CL (Edition J) G1B BAH BBV  
INT CL<sup>8</sup> G01N  
Online databases: DIALOG/BIOTECH, WPI, CHABS

(54) ~~Chemiluminescent enhancement~~

(57) Water soluble enhancer substances, generally macromolecular in nature, for example globular proteins such as vobine serum albumin, and ~~polymeric quaternary ammonium salts~~ such as poly(vinylbenzyltrimethylammonium chloride), which have the ability to inhibit light-emitting fluorophores are disclosed as permitting the stabilization, and hence increasing the light intensity, of such light-emitting fluorophores in aqueous media as compared to the intensity of the light emitted by the same quantities of such fluorophores in aqueous media in the absence of such enhancer substances.

102 (b)  
cl. 10-11

1/5

EFFECT OF BSA ON THE STANDARD CURVE  
FOR THE DETERMINATION OF TSH




FIG. 2

2/5:

# EFFECT OF ENHANCERS ON THE CHEMILUMINESCENCE OF ACRIDINIUM ESTERS






FIG. 2

3/5


0.1% BMRQ, Sul 1-1000 alkphos, 50ug/ml AMPPD, 1.2 ND Filter



0.1% BSA, Sul 1-1000 alkphos, 50ug/ml AMPPD, 1.2 ND Filter



Buffer Alone, Sul 1-1000 alkphos, 50ug/ml AMPPD, 1.2 ND Filter



4/5

# Effect of Enhancers on the Detection of Alkaline Phosphatase




FIG. 6

5/5




FIG. 7




FIG. 8

CHEMILUMINESCENCE ENHANCEMENTFIELD OF THE INVENTION

This invention relates to improvements in the detectability of electromagnetic, including optically detectable, energy released by the decomposition of chemiluminescent chemical compounds in aqueous media. More particularly, this invention  
5 relates to enhanced detection of electromagnetic energy released by the decomposition of chemiluminescent compounds used to determine the presence, concentration or structure of a substance in an aqueous sample, particularly when such ~~chemiluminescent compounds are used to detect the presence or determine the~~  
10 ~~concentration of chemical or biological substances by art-recognized immunoassay techniques~~, chemical assays or nucleic acid probe assays, or when they are used as direct chemical/physical probes for studying the molecular structures or microstructures of various macromolecules: synthetic polymers,  
15 proteins, nucleic acids and the like.

BACKGROUND OF THE INVENTION

The decomposition of chemiluminescent chemical compounds to release electromagnetic, and especially optically detectable, energy -- usually luminescence in the form of visible light -- is  
20 well known and understood. The incorporation of such light emitting reactants in art-recognized immunoassays, chemical assays, nucleic acid probe assays and chemical/physical probe techniques as the means by which the analyte, a substance whose

presence, amount or structure is being determined, is actually identified or quantified has assumed increasing importance in recent years, particularly with the advent of enzymatically-cleavable 1,2-dioxetanes; see, for example, copending Bronstein U.S. patent application Serial No. 889,523, "Method of Detecting a Substance Using Enzymatically-Induced Decomposition of Dioxetanes", filed July 24, 1986; Bronstein et al U.S. patent application Serial No. 140,035, "Dioxetanes for Use in Assays", filed December 31, 1987 and Edwards U.S. patent application Serial No. 140,197, Synthesis of 1,2-Dioxetanes and Intermediates Therefor", filed December 31, 1987.

Reactions that produce chemiluminescence exemplify yet another instance in which the medium, although not the message, can determine the intensity of the message transmitted. Chemiluminescent compounds that, upon decomposition in substances such as moderately polar or polar aprotic organic solvents, e.g., n-butanol, acetonitrile, dimethylsulfoxide or dimethylformamide, produce fluorophores that in turn emit light of adequate intensity for easy detection and quantitation will produce light of considerably lessened intensity when decomposed in a polar protic environment, and especially in aqueous media. But since all biological systems are aqueous -- indeed, man himself is 97% water -- the need to enhance the intensity of light produced by chemiluminescent labels or substrates in immunoassays, nucleic acid probe assays, chemical/physical probe techniques and other bioassays is obvious. One way to provide such enhancement, of course, is to use expensive optical or electronic equipment: single photon counters, luminometers, scintillation counters, etc. The present invention provides a far less expensive yet



equally effective way of providing the needed light enhancement in aqueous media, and in many cases provides enhanced light intensity to a degree which permits detection by simple, inexpensive means, such as with a camera, instead of with complex  
5 detection instruments.

The present invention also permits the detection of lesser concentrations of analytes using the same quantities of chemiluminescent chemical compounds used in hitherto-practiced methods, and concomitantly permits the use of lessened amounts of  
10 chemiluminescent chemical compounds to detect the same concentrations of analytes as compared to those necessary in hitherto-practiced methods. By practicing this invention the intensity of light emitted by fluorophore decomposition products of chemiluminescent chemical compounds can be enhanced by a  
15 factor of at least 10%, but usually at least tenfold and oftentimes by factors of at least 100 to 1,000,000 times the intensities obtainable in aqueous media using the same chemiluminescent compounds in hitherto-practiced methods.

While we do not wish to be bound by any theory or mechanism  
20 advanced to explain the operation of this invention, we believe that our enhancer substances act in a polar protic environment, such as an aqueous medium, to bind fluorophore-containing fragments resulting from the decomposition of a chemiluminescent chemical compound and maintain such fragments in a stabilized  
25 conformation, possibly by hydrophobic or ionic interaction, or both, between the enhancer substance and the fluorophore-containing fragment. This we believe in turn inhibits the fluorophore from releasing all or a substantial part of its excitational energy through non-light emitting pathways:

vibrational relaxation in which energy is emitted as heat rather than light, intersystem crossing to other lower energy states, or other such mechanisms.

#### SUMMARY OF THE INVENTION

5           It has now been discovered that certain ~~water-soluble~~  
~~naturally-occurring and synthetic substances~~, generally  
macromolecular in nature, for example water soluble globular  
proteins that include hydrophobic regions: mammalian serum  
albumins such as bovine serum albumin (BSA) and human serum  
10   albumin (HSA), or ~~water-soluble polymeric quaternary ammonium~~  
~~salts: poly(vinylbenzyltrimethyl-ammonium chloride) (TMQ) or~~  
~~poly[vinylbenzyl(benzyltrimethyl-ammonium chloride)] (BDMQ),~~  
permit the stabilization, and hence ~~increase the light intensity,~~  
~~of light-emitting fluorophores produced by the decomposition of~~  
15   ~~chemiluminescent chemical compounds in aqueous media.~~ Such  
chemiluminescent compounds include, but are not limited to,  
thermally, chemically, electrochemically and enzymatically  
~~cleavable 1,2-dioxetanes;~~ acridinium esters; lucigenin, a dimer  
of N-substituted acridines; luciferin, and the like, and mixtures  
20   of such chemiluminescent compounds with each other and with one  
or more auxiliary fluorophores, e.g., fluorescein, that accept  
energy from energy-emitting fluorophores produced by the  
decomposition of chemiluminescent compounds and in turn emit  
detectable energy. By virtue of the presence of effective  
25   amounts of an enhancer substance or substances the intensity of  
the light emitted in aqueous medium by the thus-stabilized  
fluorophores is increased significantly as compared to the

intensity of light emitted by the same quantities of fluorophores in the absence of such enhancers.

It is, therefore, an object of this invention to provide improvements in the detectability of electromagnetic, e.g.,  
5 optically detectable, energy released by the decomposition of chemiluminescent chemical compounds in aqueous media.

Another object of this invention is to provide means for enhanced detection of electromagnetic, e.g., optically  
10 detectable, energy released by the decomposition of chemiluminescent chemical compounds used to detect the presence or determine the concentration or structure of a substance in an aqueous sample.

A further object of this invention is to provide improvements in the detectability of electromagnetic, e.g.,  
15 optically detectable, energy released by the decomposition of chemiluminescent chemical compounds used to detect the presence or determine the concentration of chemical or biological substances by art-recognized immunoassay, chemical assay or nucleic acid probe assay techniques.

20 A still further object of this invention is to provide improvements in the detectability of electromagnetic, e.g., optically detectable, energy released by the decomposition of chemiluminescent chemical compounds for studying molecular structures or microstructures.

25 Yet another object of this invention is to provide aqueous compositions comprising water soluble naturally-occurring and synthetic enhancer substances which enable the stabilization, and hence increase the light intensity, of light-emitting fluorophores produced by the decomposition of chemiluminescent

chemical compounds in aqueous media.

These and other objects, as well as the nature, scope and utilization of this invention, will become readily apparent to those skilled in the art from the following description, the  
5 drawings and the appended claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows plots of the luminescence intensity signals obtained in the TSH assays of Example 46 performed in the presence (Curve "A") and absence (Curve "B") of BSA.

10 FIG. 2 shows plots of the light emission resulting from the decomposition of the acridinium ester used to detect the Anti-TSH-IgG of Example 47 in the absence ("Control") and presence ("Enhanced") of a BDMQ/fluorescein disodium salt enhancer.

15 FIGS. 3-5 show the luminescence rate spectra of the emitting dioxetane fragment with and without enhancer: evaluated in Example 4 (0.1% BDMQ; FIG. 3) and Example 7 (1.0% BSA; FIG. 4), together with the luminescence rate spectrum of Example 30's buffer control (FIG. 5).

20 FIG. 6 shows a plot of Relative Turner Units (RTU) versus alkaline phosphatase concentration for the various systems of Example 48.


FIGS. 7 and 8 are reproductions of the photographs described in Example 49 taken of a substrate solution without (FIG. 7) and with (FIG. 8) BSA enhancer.

DETAILED DESCRIPTION OF THE INVENTION

The enhancer substances used in practicing this invention are water soluble naturally-occurring or synthetic materials which can provide a hydrophobic microenvironment of reduced polarity for fluorophore-containing fragments resulting from the decomposition of a chemiluminescent chemical compound contained in a polar medium, i.e., a medium consisting of water as a solvent or a mixture of water and other largely or entirely polar substances, such as methanol, acetonitrile, dimethylsulfoxide, dimethylformamide, or the like.

As noted above, included among such enhancer substances are macromolecular globular proteins, generally ones having molecular weights ranging from about 1000 to about 600,000 daltons, and preferably from about 40,000 to about 100,000 daltons, as determined by SDS gel electrophoresis, that include hydrophobic regions: mammalian serum albumins such as BSA, HSA, AFP and the like; globular proteins such as mammalian IgG, IgE, Protein A, avidins, and the like; serum lipoproteins, apolipoproteins, and the like.

Synthetic oligomeric or polymeric enhancer substances that can be used in practicing this invention include, first of all, water soluble poly(vinylaryl quaternary ammonium salts), such as the poly(vinylbenzyl quaternary ammonium salts) having the formula:



In this formula each of  $R_1$ ,  $R_2$  and  $R_3$  can be a straight or branched chain unsubstituted alkyl group having from 1 to 20 carbon atoms, inclusive, e.g., methyl, ethyl, n-butyl, t-butyl, cetyl, or the like; a straight or branched chain alkyl group having from 1 to 20 carbon atoms, inclusive, substituted with one or more hydroxy, alkoxy, e.g., methoxy, ethoxy, benzyloxy or polyoxethylethoxy, aryloxy, e.g., phenoxy, amino or substituted amino, e.g., methylamino, amido, e.g., acetamido or cholesterylloxycarbonylazido, or fluoroalkane or fluoroaryl, e.g., heptafluorobutyl, groups, an unsubstituted monocycloalkyl group having from 3 to 12 ring carbon atoms, inclusive, e.g., cyclohexyl or cyclooctyl, a substituted monocycloalkyl group having from 3 to 12 ring carbon atoms, inclusive, substituted with one or more alkyl, alkoxy or fused benzo groups, e.g., methoxycyclohexyl or 1,2,3,4-tetrahydronaphthyl, a polycycloalkyl group having 2 or more fused rings, each having from 5 to 12 carbon atoms, inclusive, unsubstituted or substituted with one or more alkyl, alkoxy or aryl groups, e.g., 1-adamantyl or 3-phenyl-1-adamantyl, an aryl, alkaryl or aralkyl group having at least one ring and from 6 to 20 carbon atoms in toto, unsubstituted or substituted with one or more alkyl, aryl, or fluoroalkane or fluoroaryl groups, e.g., phenyl, naphthyl, pentafluorophenyl, ethylphenyl, benzyl, hydroxybenzyl, phenylbenzyl or

dehydroabietyl; at least two of  $R_1$ ,  $R_2$  and  $R_3$ , together with the quaternary nitrogen atom to which they are bonded, can form a saturated or unsaturated, unsubstituted or substituted nitrogen-containing, nitrogen and oxygen-containing or nitrogen and sulfur-containing ring having from 3 to 5 carbon atoms, inclusive, and 1 to 3 heteroatoms, inclusive, and which may be benzoanylated, e.g., 1-pyridyl, 1-(3-alkyl or aralkyl)imidazolium, morpholino, piperidino or acylpiperidino, benzoxazole, benzthiazole or benzamidazole.


10       The symbol  $X^-$  represents a counterion which can include, alone or in combination, moieties such as halide, i.e., fluoride, chloride, bromide or iodide, sulfate, alkylsulfonate, e.g., methylsulfonate, arylsulfonate, e.g., p-toluenesulfonate, substituted arylsulfonate, e.g., anilinonaphthylenesulfonate  
15       (various isomers), lucifer yellow CH and diphenylanthracene-sulfonate, perchlorate, alkanoate, e.g., acetate, arylcarboxylate, e.g., fluorescein or fluorescein derivatives, benzoheterocyclicarylcboxylate, e.g., 7-diethylamino-4-cyanocoumarin-3-carboxylate, phosphate, or substituted  
20       monoaryloxyphosphate, e.g., a 3-(2'-spiroadamantane)-4-methoxy-(3"-phosphoryloxy)phenyl-1,2-dioxetane dianion or other dianions indicated in formula III, *infra*.

      The symbol  $n$  represents a number such that the molecular weight of such poly(vinylbenzyl quaternary ammonium salts) will  
25       range from about 800 to about 200,000, and preferably from about 20,000 to about 70,000, as determined by intrinsic viscosity or LALLS techniques.

~~Illustrative of such water soluble poly(vinylbenzyl  
quaternary ammonium salts) are TMQ, BDMQ, and the like.~~

These vinylbenzyl quaternary ammonium salt polymers can be prepared by free radical polymerization of the appropriate precursor monomers or by exhaustive alkylation of the  
5 corresponding tertiary amines with polyvinylbenzyl chloride. This same approach can be taken using other polymeric alkylating agents such as chloromethylated polyphenylene oxide or polyepichlorohydrin. The same polymeric alkylating agents can be  
10 used as initiators of oxazoline ring-opening polymerization, which, after hydrolysis, yields polyethyleneimine graft copolymers. Such copolymers can then be quaternized, preferably with aralkyl groups, to give the final polymeric enhancer substance.

15 Water soluble acetals of a polyvinylalcohol and a formylbenzyl quaternary ammonium salt, having the formula:



(II)

wherein each  $\text{R}_4$  is the same or a different aliphatic substituent and  $\text{X}_1$  is an anion, as disclosed and claimed in Bronstein-Bonte  
20 et al U.S. Patent No. 4,124,388, can also be used as enhancer substances in practicing this invention. And, the individual vinylbenzyl quaternary ammonium salt monomers used to prepare the poly(vinylbenzyl quaternary ammonium salts) of formula I above can also be copolymerized with other vinylbenzyl quaternary



ammonium salt monomers whose polymers are depicted in formula I,  
or with other ethylenically unsaturated monomers having no  
quaternary ammonium functionality, to give polymers such as those  
disclosed and claimed in Land et al U.S. Patent No. 4,322, 489;  
5 Bronstein-Bonte et al U.S. Patent No. 4,340,522, Land et al U.S.  
Patent No. 4,424,326; Bronstein-Bonte et al U.S. Patent No.  
4,503,138 and Bronstein-Bonte U.S. Patent No. 4,563,411, all of  
which polymers can also be used as enhancer substances in  
practicing this invention. Preferably these quaternized polymers  
10 will have molecular weights within the ranges given above for the  
poly(vinylbenzyl quaternary ammonium salts) of formula I.

Other water soluble oligomeric, homopolymeric and  
copolymeric materials can be used as enhancer substances in  
addition to or instead of the foregoing polymers, including:

- 15 -poly-N-vinyl oxazolidinones;
- polyvinyl carbamates (e.g., polyvinyl propylene carbamate);
- polyhydroxyacrylates and methacrylates [e.g., poly( $\beta$ -  
hydroxyethyl)methacrylate and polyethyleneglycol  
monomethacrylates];
- 20 -amine-containing oligomers (e.g., Jeffamines) quaternized  
with alkylating or aralkylating agents;
- synthetic polypeptides (e.g., polylysine co  
phenylalanine);
- polyvinylalkylethers (e.g., polyvinyl methyl ether);
- 25 -polyacids and salts thereof [e.g., polyacrylic acids,  
polymethacrylic acids, polyvinylbenzoic acid, polyethylene-  
sulfonic acid, polyacrylamidomethylpropanesulfonic acid,  
polymaleic acid and poly(N-vinyl succinamidic acid)];

-polyacrylamides and polymethacrylamides derived from ammonia or cyclic and acyclic primary or secondary amines;

-polyvinyl alcohol and polyvinyl alcohol copolymers with vinyl acetate, ethylene and the like;

5        -poly 2-, 3- or 4-vinylpyridinium salts where the heterocyclic nitrogen atom is bonded to a group as defined for  $R_1$ ,  $R_2$  and  $R_3$  in formula I above;

-polyvinylalkylpyrrolidinones (e.g., polyvinylmethylpyrrolidinones);

10       -polyvinylalkyloxazolidones (e.g., polyvinylmethyloxazolidones);

-branched polyethyleneimines, acylated branched polyethyleneimines, or acylated branched polyethyleneimines further quaternized with alkyl or aralkyl groups;

15       -poly N-vinylamines derived from ammonia or cyclic and acyclic primary or secondary amines, and salts thereof;

-polyvinylpiperidine;

-polyacryloyl, polymethacryloyl or 4-vinylbenzoyl aminimides where the three substituents on the positively charged nitrogen atom may be any of the  $R_1$ ,  $R_2$  and  $R_3$  groups defined in formula I above.

20       Here too, these oligomeric or polymeric enhancer substances preferably will have molecular weights within the ranges given above for the poly(vinylbenzyl quaternary ammonium salts) of formula I.

25       Water soluble monomeric quaternary soaps whose nitrogen atom has at least one benzyl substituent and in which the remaining nitrogen substituents correspond to the definitions given for  $R_1$ ,  $R_2$ ,  $R_3$  and X in formula I, supra, e.g.,


cetyldimethylbenzylammonium chloride or cetyldibenzylmethyl ammonium bromide, can also be used as enhancer substances when practicing this invention.

5 The amount of enhancer substance or mixture of enhancer substances employed when practicing this invention can vary within wide limits depending on the particular enhancer substance(s) chosen, the amount and type of chemiluminescent compound(s) present, etc. For example, certain enhancers, such as BSA, exhibit an optimum concentration, depending primarily on  
10 the chemiluminescent compound present, beyond which the addition of further amounts of the enhancer produces no further increase in light intensity. Other enhancers, such as TMQ, provide increased enhancement with increasing concentration. In general, however, amounts of enhancer substance ranging from about 0.01%  
15 to about 25%, and preferably from about 0.1% to about 5%, based on the weight of enhancer divided by the weight of aqueous medium, will be employed.

Any chemiluminescent chemical compound that (1) can be induced to decompose to yield a moiety in an excited state, such  
20 moiety having a heteropolar character that makes it susceptible to environmental effects, and particularly to dampening or diminution of luminescence in a polar protic environment, and that (2) is usable to determine the presence, concentration or structure of a substance in a polar protic environment,  
25 particularly a substance in an aqueous sample, can be used in practicing this invention.

1,2-Dioxetanes such as the enzymatically-cleavable dioxetanes disclosed and claimed in the aforementioned copending Bronstein, Bronstein et al and Edwards applications and their

thermally, chemically and electrochemically cleavable analogs form one class of usable chemiluminescent chemical compounds. These 1,2-dioxetanes can be represented by the general formula:



5 In this formula T is an unsubstituted or substituted cycloalkyl, aryl, polyaryl or heteroatom group, e.g., an unsubstituted cycloalkyl group having from 6 to 12 ring carbon atoms, inclusive; a substituted cycloalkyl group having from 6 to 12 ring carbon atoms, inclusive, and having one or more substituents  
10 which can be an alkyl group having from 1 to 7 carbon atoms, inclusive, or a heteroatom group which can be an alkoxy group having from 1 to 12 carbon atoms, inclusive, such as methoxy or ethoxy, a substituted or unsubstituted aryloxy group, such as phenoxy or carboxyphenoxy, or an alkoxyalkyloxy group, such as  
15 methoxyethoxy or polyethyleneoxy, or a cycloalkylidene group bonded to the 3-carbon atom of the dioxetane ring through a spiro linkage and having from 6 to 12 carbon atoms, inclusive, or a fused polycycloalkylidene group bonded to the 3-carbon of the dioxetane ring through a spiro linkage and having two or more  
20 fused rings, each having from 5 to 12 carbon atoms, inclusive, e.g., an adamant-2-ylidene group.


The symbol Y represents a light-emitting fluorophore-forming fluorescent chromophore group capable of absorbing energy to form an excited energy state from which it emits optically detectable  
25 energy to return to its original energy state.

The symbol  $X_2$  represents hydrogen or an alkyl, aryl, aralkyl, alkaryl, heteroalkyl, heteroaryl, cycloalkyl or cycloheteroalkyl group, e.g., a straight or branched chain alkyl group having from 1 to 7 carbon atoms, inclusive; a straight or  
5 branched chain hydroxyalkyl group having from 1 to 7 carbon atoms, inclusive, or an -OR group in which R is a  $C_1$ - $C_{20}$  unbranched or branched, unsubstituted or substituted, saturated or unsaturated alkyl, cycloalkyl, cycloalkenyl, aryl, aralkyl or aralkenyl group, fused ring cycloalkyl, cycloalkenyl, aryl,  
10 aralkyl or aralkenyl group, or an  $N_1$  O or S hereto atom-containing group, or an enzyme-cleavable group containing a bond cleavable by an enzyme to yield an electron-rich moiety bonded to the dioxetane ring. Preferably  $X_2$  is a methoxy group.

The symbol Z represents hydrogen (in which case the  
15 dioxetane can be thermally cleaved via rupture of the oxygen-oxygen bond), a chemically cleavable group such as a hydroxyl group, an alkanoyl or aroyl ester group, or an alkyl or aryl silyloxy group, or an enzyme-cleavable group containing a bond cleavable by an enzyme to yield an electron-rich moiety bonded to  
20 the dioxetane ring, e.g., a bond which, when cleaved, yields an oxygen anion, a sulfur anion or a nitrogen anion, and particularly an amido anion such as a sulfonamido anion.

One or more of the substituents T,  $X_2$  and Z can also include a substituent which enhances the water solubility of the 1,2-  
25 dioxetane, such as a carboxylic acid, sulfonic acid or quaternary amino salt group, at least one of  $X_2$  and Z, and preferably Z, is an enzyme-cleavable group, and preferably an enzyme-cleavable phosphate ester group, and  $X_2$  and Y together can represent a fused fluorescent chromophore group bonded to the 4-carbon atom

of the dioxetane ring through a spiro linkage, e.g., one having the general formula:



(IV)

5 In this formula  $X_3$  is  $\begin{array}{c} R_7 \\ | \\ C \\ | \\ R_8 \end{array}$ , - O -, - S - or -NR<sub>9</sub>, where each of R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub>, independently, is hydrogen, a branched or straight chain alkyl group having 1 to 20 carbon atoms, inclusive, e.g., methyl, n-butyl or decyl, a branched or straight chain heteroalkyl group having 1 to 7 carbon atoms, inclusive, e.g., methoxy, hydroxyethyl or hydroxypropyl; an aryl group having 1 or 2 rings, e.g., phenyl; a heteroaryl group having 1 or 2 rings, e.g., pyrrolyl or pyrazolyl; a cycloalkyl group having 3 to 7 carbon atoms, inclusive, in the ring, e.g., cyclohexyl; a heterocycloalkyl group having 3 to 6 carbon atoms, inclusive, in the ring, e.g., dioxane; an aralkyl group having 1 or 2 rings, e.g., benzyl; an alkaryl group having 1 or 2 rings, e.g., tolyl; or an enzyme-cleavable group as defined above; and each R<sub>6</sub>, independently, can be hydrogen; an electron-withdrawing group, such as a perfluoroalkyl group having between 1 and 7 carbon atoms, inclusive, e.g., trifluoromethyl; a halogen; CO<sub>2</sub>H, Z<sub>1</sub>CO<sub>2</sub>H, SO<sub>3</sub>H, NO<sub>2</sub>, Z<sub>1</sub>NO<sub>2</sub>, C=N, or Z<sub>1</sub>C=N, where Z<sub>1</sub> is a branched or straight chain alkyl group having 1 to 7 carbon atoms, inclusive, e.g., methyl, or an aryl group having 1 or 2 rings, e.g., phenyl; an electron-donating group, e.g., a branched or

straight chain C<sub>1</sub>-C<sub>7</sub> alkoxy group, e.g., methoxy or ethoxy; an  
aralkoxy group having 1 or 2 rings, e.g., phenoxy; a branched or  
straight chain C<sub>1</sub>-C<sub>7</sub> hydroxyalkyl group, e.g., hydroxymethyl or  
hydroxyethyl; a hydroxyaryl group having 1 or 2 rings, e.g.,  
5 hydroxyphenyl; a branched or straight chain C<sub>1</sub>-C<sub>7</sub> alkyl ester  
group, e.g., acetate; or an aryl ester group having 1 or 2 rings,  
e.g., benzoate; a heteroaryl group having 1 or 2 rings, e.g.,  
benzoxazole, benzthiazole, benzimidazole or benztriazole; or  
hydrogen or an enzyme-cleavable or chemically cleavable group Z  
10 as defined herein, with at least one of R<sub>6</sub> being Z. Furthermore,  
all of the R<sub>6</sub> groups together can form a ring which can be  
substituted or unsubstituted, and one or more of the substituents  
T, X<sub>2</sub> and Z can also include a substituent which enhances the  
water solubility of the 1,2-dioxetane, such as a carboxylic acid,  
15 sulfonic acid or quaternary amino salt group.

Included among the substances whose residues can be present  
in such 1,2-dioxetanes as fluorescent chromophore (Y or  $\begin{matrix} X_2 \\ \diagup \quad \diagdown \\ Y \quad Z \end{matrix}$ )

20

groups are:

-anthracene and anthracene derivatives, e.g., 9,10-  
diphenylanthracene, 9-methylanthracene, 9-anthracene  
carboxaldehyde, anthrylalcohols and 9-phenylanthracene;

25

-rhodamine and rhodamine derivatives, e.g., rhodols,  
tetramethyl rhodamine, tetraethyl rhodamine, diphenyldimethyl  
rhodamine, diphenyldiethyl rhodamine and dinaphthyl rhodamine;

-fluorescein and fluorescein derivatives, e.g., 5-  
iodoacetamido fluorescein, 6-iodoacetamido fluorescein and  
30 fluorescein-5-maleimide;

-coumarin and coumarin derivatives, e.g., 7-dialkylamino-4-methylcoumarin, 4-bromomethyl-7-methoxycoumarin and 4-bromomethyl-7-hydroxy coumarin;

5       -erythrosin and erythrosin derivatives, e.g., hydroxy erythrosins, erythrosin-5-iodoacetamide and erythrosin-5-maleimide;

-aciridine and aciridine derivatives, e.g., hydroxy aciridines and 9-methyl aciridine;

10       -pyrene and pyrene derivatives, e.g., N-(1-pyrene) iodoacetamide, hydroxy pyrenes and 1-pyrenemethyl iodoacetate;

-stilbene and stilbene derivatives, e.g., 6,6'-dibromostilbene and hydroxy stilbenes;

15       -naphthalene and naphthalene derivatives, e.g., 5-dimethylamino naphthalene-1-sulfonic acid and hydroxy naphthalenes;

20       -nitrobenzoxadiazoles and nitrobenzoxadiazole derivatives, e.g., hydroxy nitrobenzoxadiazoles, 4-chloro-7-nitrobenz-2-oxa-1,3-diazole, 2-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)methylaminoacetaldehyde and 6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoic acid;

-quinoline and quinoline derivatives, e.g., 6-hydroxyquinoline and 6-aminoquinoline;

-acridine and acridine derivatives, e.g., N-methylacridine and N-phenylacridine;

25       -acidoacridine and acidoacridine derivatives, e.g., 9-methylacidoacridine and hydroxy-9-methylacidoacridine;

-carbazole and carbazole derivatives, e.g., N-methylcarbazole and hydroxy-N-methylcarbazole;



-fluorescent cyanines, e.g., DCM (a laser dye), hydroxy cyanines, 1,6-diphenyl-1,3,5-hexatriene, 1-(4-dimethyl aminophenyl)-6-phenylhexatriene and the corresponding 1,3-butadienes;

5        -carbocyanines and carbocyanine derivatives, e.g., phenylcarbocyanine and hydroxy carbocyanines;

      -pyridinium salts, e.g., 4(4-dialkyldiaminostyryl)N-methyl pyridinium iodate and hydroxy-substituted pyridinium salts;

      -oxonols; and


10       -resorofins and hydroxy resorofins.

      When using an enzymatically-cleavable 1,2-dioxetane, cleavage can be accomplished using an enzyme such as an alkaline phosphatase that will cleave a bond in, for example, a Z substituent such as a phosphate ester group to produce a Y anion  
15       in a charge transfer state that will, in turn, destabilize the dioxetane and cleave its oxygen-oxygen bond. Cleavage can also be accomplished by using an enzyme such as an oxidoreductase enzyme that will cleave the oxygen-oxygen bond directly; see the aforementioned Bronstein and Bronstein et al pending U.S. patent  
20       applications.

      Besides a phosphate ester group, Z in formulas III and IV above can be an enzyme-cleavable alkanoyloxy group, e.g., an acetate ester group, or an oxacarboxylate group, 1-phospho-2,3-diacylglyceride group, 1-thio-D-glucoside group, adenosine  
25       triphosphate analog group, adenosine diphosphate analog group, adenosine monophosphate analog group, adenosine analog group,  $\alpha$ -D-galactoside group,  $\beta$ -D-galactoside group,  $\alpha$ -D-glucoside group,  $\beta$ -D-glucoside group,  $\alpha$ -D-mannoside group,  $\beta$ -D-mannoside group,  $\beta$ -D-fructofuranoside group,  $\beta$ -D-glucosiduronate group, p-


toluenesulfonyl-L-arginine dye ester group or p-toluenesulfonyl-L-arginine dye amide group.

Preferred enzymatically-cleavable 1,2-dioxetanes for use in practicing this invention are the 3-(2'-spiroadamantane)-4-methoxy-4-(3"-phosphoroyloxy)phenyl-1,2-dioxetane salts represented by the formula:



wherein  $M^+$  represents a cation such as alkali metal, e.g., sodium or potassium, ammonium, or a  $C_1$ - $C_7$  alkyl, aralkyl or aromatic quaternary ammonium cation,  $N(R_5)_4^+$  in which each  $R_5$  can be alkyl, e.g., methyl or ethyl, aralkyl, e.g., benzyl, or form part of a heterocyclic ring system, e.g., pyridinium, and particularly the disodium salt.

Another class of chemiluminescent compounds usable when practicing this invention includes acridinium esters or the phenanthradinium derivatives in which a phenoxycarbonyl group is present in the 9-position on an N-substituted acridine moiety, e.g., those having the general formula:



wherein  $R_{10}$  is, for example, a  $C_1$ - $C_{10}$  straight or branched chain alkyl or alkoxy group; an aryl group, preferably one having a

single aryl ring, e.g., phenyl; an amino group; a hydroxyl group,  
a carbonyl-containing group; e.g., an acetyl group, or a  
carboxylic acid or ester group;  $R_{11}$  can be any of  $R_{10}$ , hydrogen;  
a fused benzo ring, or a group suitable for conjugation to  
5 proteins or nucleic acids, e.g., an isothiocyanate group, an N-  
hydroxysuccinimide ester group, biotin or avidins, and  $X_4$  is a  
counterion which can include, alone or in combination, a halide,  
sulfate, alkylsulfonate, arylsulfonate, substituted arylsul-  
fonate, perchlorate, alkanoate, arylcarboxylate, heteroaryl-  
10 carboxylate, phosphate or substituted monoaryloxyphosphate  
moiety, an anionic oligomer or an anionic homopolymer or  
copolymer.

These acridinium esters, in the presence of a peroxide such  
as hydrogen peroxide and an alkaline substance, e.g., sodium  
15 hydroxide or potassium hydroxide, chemiluminesce from the excited  
state of the N-substituted acridone formed by cleavage of the  
phenoxy ester portion of the molecule.

One or more auxiliary fluorophores extraneous to the light-  
emitting fluorophores produced by the decomposition of the  
20 chemiluminescent compound(s) also present that will accept  
energy, especially light, from energy-emitting fluorophores  
produced by the decomposition of the chemiluminescent compound(s)  
and in turn emit detectable energy, again preferably light, can  
be used when practicing this invention. Among the auxiliary  
25 fluorophores that can be used, alone or in combination, are the  
substances listed above whose residues can be present in 1,2-  
dioxetanes as fluorescent chromophore groups. Fluorescein and  
fluorescein derivatives, including derivatives capable of  
establishing a covalent bond with the enhancer substance, are

especially preferred for use as the auxiliary fluorophore(s).

These auxiliary fluorophores can simply be admixed with the enhancer substance(s) and chemiluminescent compound(s) or bonded to either or both of these materials. Phycobiliproteins  
5 represent a naturally-occurring class of enhancer molecules in which a fluorophore is covalently bonded to a protein. When the auxiliary fluorophore is bonded to a chemiluminescent compound, it is preferably bonded to the portion of the chemiluminescent compound that, upon decomposition, forms a fragment containing  
10 the fluorophore portion of the chemiluminescent compound's molecule. In this way energy transfer is enhanced due to the two fluorophores being in close proximity to one another. Auxiliary fluorophores that are insoluble or partially insoluble in aqueous medium can be solubilized by first grafting them onto  
15 solubilizing molecules, e.g., water soluble oligomer or polymer molecules.

When admixed with the enhancer substance(s) and chemiluminescent compounds(s), the amount of auxiliary fluorophore present used can range from about 1 ng (nanogram)/mL  
20 to about 10 mg/mL of enhancer-containing solution, and preferably from about 1  $\mu$ g/mL to about 100  $\mu$ g/mL of enhancer-containing solution.

When auxiliary fluorophores covalently attached to proteins are used, the molar ratio of fluorophore to protein can range  
25 from 1 to 60, and preferably (e.g., for BSA) from 1 to 6, per molecule of protein.

~~This invention is particularly useful when conducting immunoassays, such as those employed to detect an enzyme or a member of a specific binding pair, e.g., an antigen-antibody pair~~

~~or a nucleic acid paired with a probe capable of binding to all~~  
~~or a portion of the nucleic acid.~~ Such assays include  
immunoassays used to detect a hormone such as  $\beta$ -human chorionic  
gonadotropin ( $\beta$ -hCG), thyroid stimulating hormone (TSH), follicle  
5 stimulating hormone (FSH), luteinizing hormone (LH) or the like,  
cell surface receptor assays, and nucleic acid assays used to  
detect viruses, e.g., HIV or HTLV III and cytomegalovirus, or  
bacteria, e.g., E.Coli., and histocompatibility assays; for  
typical assay protocols see the working examples, infra, as well  
10 as the aforementioned Bronstein and Bronstein et al U.S. patent  
applications. The invention can also be used in assays for a  
chemical analyte, such as potassium or sodium ions, or in assays  
for substances such as cholesterol or glucose in which the  
analyte is caused to decompose, for example using an enzyme such  
15 as cholesterol oxidase or glucose oxidase, to form a substance,  
e.g., hydrogen peroxide, capable of causing the chemiluminescent  
compound to decompose.

In order that those skilled in the art can more fully  
understand this invention, the following examples are set forth.  
20 These examples are given solely for purposes of illustration, and  
should not be considered as expressing limitations unless so set  
forth in the appended claims.

#### EXAMPLES 1 - 45

The enhancer substances listed in Table I below, in which  
25 all parts and percentages are by weight, unless otherwise stated,  
were evaluated for their light intensity-enhancing properties by  
dissolving the appropriate amount of enhancer in 0.05 M carbonate

buffer solution containing 1 mM magnesium chloride (pH = 9.5) to give the noted concentrations. To 1 ml samples of each of the resulting solutions (including the control, Example 31, containing no enhancer) there was then added sufficient 3-(2'-  
5 spiroadamantane)-4-methoxy-4-(3"-phosphoryloxy)phenyl-1,2-dioxetane disodium salt, dissolved in the same carbonate buffer solution used to dissolve the enhancer, to give a final concentration of this chemiluminescent compound of 0.125 mM. The resulting solutions were then equilibrated to 30°C, after which  
10 ~~aqueous alkaline phosphatase solution was added to give a final enzyme concentration of  $4.17 \times 10^{-10}$  M.~~ The luminescence signal of each solution was then measured at 30°C in a Turner 20 E Luminometer integrating over twenty minutes. Successful enhancers or amounts of enhancer were those that gave an  
15 enhancement factor greater than 1 (i.e., greater than that of the sample, Example 30, containing the chemiluminescent compound but no enhancer).

Table 1

<u>Example</u>	<u>Enhancer Concentration</u>	<u>Enhancement Factor</u>
1	0.1% BDMQ + fluorescein <sup>1</sup>	298.891832
2	0.1% BDMCAC <sup>2</sup> + fluorescein <sup>1</sup>	135.643835
3	1.0% BDMQ	19.026097
4	0.1% BDMQ	18.422605
5	0.25% THQ	7.194016
6	0.1% BSA	5.172073
7	1.0% BSA	4.790837
8	0.1% THQ	4.475993
9	0.1% BDMCAC	2.874500
10	1.0% PolyMAPTAC <sup>3</sup>	2.384163
11	1.0 PVP K-90 <sup>4</sup>	2.034744
12	0.01µg/ml fluorescein alone	2.004920
13	1.0% PEOX <sup>5</sup>	1.454102
14	1.0% PVP K-30 <sup>6</sup>	1.419595
15	1.0% Polybrene <sup>7</sup>	1.391839

<sup>1</sup> 0.01µg/ml Fluorescein added.

<sup>2</sup> Benzyldimethylcetylammonium chloride; TCI.

<sup>3</sup> Polymethacrylamidopropylenemethyl ammonium chloride;  
Polyscience.

<sup>4</sup> Polyvinylpyrrolidone; GAF.

<sup>5</sup> Polyethyloxazoline; Dow Chemical Co.

<sup>6</sup> Polyvinylpyrrolidinone; CTAF.

<sup>7</sup> 1,5-Dimethyl-1,5-diaza-undecamethylene  
polymethobromide; Aldrich.

Table 1 (contd).

<u>Example</u>	<u>Enhancer Concentration</u>	<u>Enhancement Factor</u>
16	0.1% Protein A <sup>8</sup> + fluorescein	1.391196
17	1.0% PEI 1000 <sup>9</sup>	1.262907
18	1.0% Polyox M-80 <sup>10</sup>	1.167327
19	0.1% PolyMAP1AC	1.140866
20	0.1% Polybrene	1.139414
21	0.1% PVP K-30	1.112314
22	0.1% PVP K-90	1.091996
23	0.1% Kelcosol Algin <sup>11</sup>	1.084700
24	0.1% Kelco SCS XL <sup>12</sup>	1.077093
25	0.1% Pluronic F127 <sup>13</sup>	1.076141
26	1.0% Polyox M-10 <sup>14</sup>	1.045022
27	1.0% Kelco SCS XL	1.043893
28	0.1% PEOX	1.025682
29	0.1% PEI 1000	1.023954

---

8 Staphylococcus-derived; Sigma.

9 Polyethyleneimine; Dow Chemical Co.

10 Polyethyleneoxide, Union Carbide Corp.

11 Alginic acid (sodium salt); Merck.

12 Sodium cellulose sulfate; Merck.

13 Polyethylenepropylene glycol; BASF Wyandotte.

14 Polyoxazoline; Dow Chemical Co.



Table 1 (contd).

<u>Example</u>	<u>Enhancer Concentration</u>	<u>Enhancement Factor</u>
30	Buffer solution alone (no enhancer)	1.00000
31	1.0% Pluronic F127	0.959475
32	0.1% 18-crown-6 ether <sup>15</sup>	0.953054
33	0.1% Gum Ghatti <sup>16</sup>	0.946162
34	0.1% Protein A	0.940106
35	0.1% PVHP <sup>17</sup>	0.933433
36	0.1% Polyox M-80	0.930873
37	0.1% Polyox M-10	0.907289
38	1.0% PEG <sup>18</sup>	0.893920
39	1.0% 18-crown-6 ether	0.871326
40	1.0% Kelcosol Algin <sup>19</sup>	0.786052

---

15 1,4,7,10,13,16-hexaoxacyclooctadecane; Aldrich.

16 Cat. No. G0378; Sigma.

17 Polyvinylhydrogenphthalate; Eastman Kodak 5527.

18 Polyethylene glycol, molecular weight 8000,  
for biological use, P2139; Sigma.

19 Alginate; Kelco Co.

TABLE 1 (contd).

<u>Example</u>	<u>Enhancer Concentration</u>	<u>Enhancement Factor</u>
41	0.1% Polyox M-301 <sup>20</sup>	0.765806
42	0.1% PEG	0.751353
43	1.0% Gum Ghatti	0.558062
44	1.0% Polyox M-301	0.523886
45	1.0% PVHP	0.029226

---

<sup>20</sup> Polyethylene oxide; Union Carbide.

The light emission spectra of the samples of Examples 4, 7 and 30 are shown in FIGS. 3, 4 and 5, respectively, with light intensity being measured on the abscissa (X axis) and time on the ordinate (Y axis) of each plot.

5

EXAMPLE 46

A TSH assay was carried out as follows:

MATERIALS:

6a.107-11



~~Mouse monoclonal anti-TSH- $\beta$  antibody was used to coat 1/8 inch beads for analyte capture. Mouse monoclonal anti-TSH-  
antibody was conjugated with alkaline phosphatase and used as a  
detection antibody.~~

TSH was obtained from Calbiochem, Catalog No. 609396, and BSA (type V - fatty acid free) was obtained from Sigma, Catalog No. A6003.

The buffer solution used for the analyte and conjugate contained 0.1 M Tris-HCl, 1mM MgCl<sub>2</sub>, and 2% by weight BSA (pH=7.5) The substrate buffer solution contained 0.1 M Tris, 0.1 mM MgCl<sub>2</sub>, 0.1% by weight BSA (pH=9.5), and 3-(2'-spiroadamantane)-4-methoxy-4-(3"-phosphoryloxy)phenyl-1,2-dioxetane disodium salt as the chemiluminescent compound. (50  $\mu$ g/ml).

PROTOCOL:

15  $\mu$ l of a TSH-containing analyte solution was mixed with  
135  $\mu$ l of conjugate antibody solution. Two 1/8 inch beads coated  
as described above were added to the solution and incubated for 2  
5 hours at 23°C. The beads were then washed four times with 0.1 M  
Tris (pH = 7.5) and transferred to a reaction tube. 200  $\mu$ l of the  
same chemiluminescent compound used in the substrate buffer  
solution described above was added to the tube. Following an  
incubation period of 20 minutes, light emission was recorded as  
10 ten second counts using a Berthold Clinilumat Luminescence  
Analyzer.

An identical TSH assay was also performed with the same  
concentration of substrate in the same buffer without BSA for the  
sake of comparison. As shown in FIG. 1, a plot of the data in  
15 Table II below, the BSA-containing sample (Curve A) showed  
greater luminescence intensity for a given TSH concentration than  
the sample without BSA (Curve B).

Table II

20	TSH Concentration	Luminescent Signal	(Counts/ <sup>10</sup> sec x 10 <sup>-4</sup> )
	( $\mu$ U/ml)	With 0.10% BSA	Without BSA
	1	0.48	0.25
	2	1.1	0.49
	4	1.7	1.1

EXAMPLE 47

The enhancement of acridinium ester luminescence from an anti-TSH-IgG-acridinium ester ("AE") conjugate (Ciba-Corning) was shown by means of the following procedure.

5 To 50  $\mu$ l portions of anti-TSH-IgG-AE conjugate containing 30 mg IgG/ml with 2-3 labels in luminometer tubes there were added the amounts of an aqueous solution containing 0.1% BDMQ and 0.01 mg/ml of fluorescein disodium salt indicated in Table III below. Each tube was placed in a Berthold Clinilumat Luminometer and a  
10 luminescent reaction initiated by injecting 200  $\mu$ l of 50 mM aqueous sodium hydroxide solution containing 0.05% hydrogen peroxide.

BDMQ/fluorescein-enhanced light emission from the acridinium ester, at the 10 and 50  $\mu$ l levels, as compared to the control, is  
15 shown in Table III and illustrated by the plots of FIG. 2.

Table III

	<u>Enhancer Concentration, <math>\mu</math>l</u>	<u>Light Intensity (10 second integral)</u>
	None (control)	127,479
20	10	169,753
	50	188,885
	100	82,437

EXAMPLE 48

An assay for alkaline phosphatase was conducted in the following manner.

COMPONENTS:

5     Buffer: 0.05M carbonate, 1mM MgCl<sub>2</sub> at pH 9.5

Substrate: 3-(2'-spiroadamantane)-4-methoxy-4-(3"-phosphoryloxy)phenyl-1,2-dioxetane disodium salt at 0.4 mM concentration

10    Alkaline Phosphatase: stock solution at 1.168 µg/ml in the buffer

Enhancing Systems Tested:

1. Buffer alone, control
2. Buffer plus 0.1% BSA
- 15    3. Buffer plus 0.1% BSA-fluorescein (BSA to fluorescein molar ratio of 1 to 3)
4. Buffer plus 0.1% BDMQ
5. Buffer plus 0.1% BDMQ and fluorescein (0.01 mg of fluorescein disodium salt added per ml of BDMQ).

20    Serial dilutions of alkaline phosphatase stock solutions were made in tubes with final enzyme concentrations of:

	4.17 X 10 <sup>-11</sup> M	1.67 X 10 <sup>-15</sup> M
	8.34 X 10 <sup>-12</sup> M	8.34 X 10 <sup>-16</sup> M
	1.67 X 10 <sup>-12</sup> M	4.17 X 10 <sup>-16</sup> M
	3.34 X 10 <sup>-13</sup> M	2.09 X 10 <sup>-16</sup> M
5	6.68 X 10 <sup>-14</sup> M	1.0 X 10 <sup>-16</sup> M
	1.34 X 10 <sup>-14</sup> M	5.0 X 10 <sup>-17</sup> M
	3.34 X 10 <sup>-15</sup> M	2.5 X 10 <sup>-17</sup> M

PROCEDURE:

10 Duplicate tubes at each of the above concentrations of alkaline phosphatase also containing 0.4 mM 3-(2'-spiroadamantane)-4-methoxy-4-(3"-phosphoryloxy)phenyl-1,2-dioxetane disodium salt in various enhancing systems were incubated at 30°C. Systems 1, 4 and 5 were incubated for 20 minutes, while systems 2 and 3 were incubated for 80 minutes.

15 After incubation, 30 second light integrals were measured in a Turner 20E Luminometer, and the effect of the enhancers tested on the limits of detection of alkaline phosphatase is shown in Table IV.

Table IV

	<u>Addition</u>	<u>Concentration of Alkaline Phosphatase for 2X Background</u>	<u>Minimum Detectable Conc. of Alkaline Phosphatase</u>
5	None	$1.0 \times 10^{-14}M$	$1.67 \times 10^{-15}M$ (1.12)
	0.1% BSA	$9.5 \times 10^{-15}M$	$8.34 \times 10^{-16}M$ (1.06)
	0.1% BSA:Fluorescein	$1.3 \times 10^{-15}M$	$4.17 \times 10^{-16}M$ (1.04)
	0.1% BDMQ	$4.0 \times 10^{-15}M$	$1.00 \times 10^{-16}M$ (1.07)
	0.1% BDMQ:Fluorescein	$3.4 \times 10^{-15}M$	$2.09 \times 10^{-16}M$ (1.06)
10	<hr/>		
	1 Buffer: 0.05 M Carbonate, 1 mM $MgCl_2$ , pH = 9.5. Temperature: 30°C. Chemiluminescent compound concentration is 0.4 mM.		
15	2 The number in parentheses is the multiple of background at the indicated concentration.		

EXAMPLE 49

The ability to detect luminescence photographically by means of this invention was demonstrated in the following manner.

COMPONENTS:

20 Buffer: 0.1M Tris, 1 mM  $MgCl_2$  at pH 9.8 prepared with 0.1% BSA and without BSA, (BSA purchased from Sigma, Catalog number A7906).



Enzyme: 0.05  $\mu$ g ~~Alkaline~~ Phosphatase ( $3.6 \times 10^{-13}$  moles)  
purchased from Biozyme Corporation.

Membrane: 0.45  $\mu$  pore-size nitrocellulose.

Substrate: 3-(2'-spiroadamantane)-4-methoxy-4-(3"-  
5 phosphoryloxy)phenyl-1,2-dioxetane disodium salt  
at 0.08 mM concentration.

PROTOCOL:

~~Enzyme solution was spotted on a dry nitrocellulose membrane.~~  
Subsequently, the membrane was blocked with 2.5% dry milk solids  
10 and 1% fish gelatin in phosphate buffered saline at pH 7.3. The  
blocked membrane was washed with the substrate solution in  
buffers containing no BSA, and with BSA.

The membrane was placed in a camera luminometer and 10 minute  
exposures were recorded on Type 612 Polaroid Black and White  
15 Instant Film. Reproductions of the photographs obtained appear  
as FIGS. 7 and 8.

The above discussion of this invention is directed primarily  
to preferred embodiments and practices thereof. It will be

readily apparent to those skilled in the art that further changes  
and modifications in the actual implementations of the concepts  
described herein can easily be made without departing from the  
spirit and scope of the invention as defined by the following  
5 claims.

**WE CLAIM:**

1. In a process carried out in aqueous medium in which electromagnetic energy released by the decomposition of a chemiluminescent chemical compound is detected to determine the presence, concentration or structure of an analyte, the improvement comprising carrying out the process in the presence of an amount of a water soluble substance sufficient to enhance the intensity of the released detectable energy as compared to the intensity of the detectable energy released in the absence of the enhancer substance.

2. The process of claim 1 in which the chemiluminescent chemical compound's decomposition results in the formation of a light-emitting fluorophore.

3. The process of claim 2 in which the enhancer substance has the ability to inhibit the fluorophore from releasing energy through non-light emitting pathways.

4. The process of claim 3 in which the enhancer substance comprises a naturally-occurring or synthetic macromolecular substance that can provide a hydrophobic microenvironment for the fluorophore.

5. The process of claim 4 in which the enhancer substance comprises a naturally-occurring macromolecular substance.

6. The process of claim 5 in which the macromolecular substance is a globular protein that includes hydrophobic regions.

7. The process of claim 6 in which the globular protein is a mammalian serum albumin.

8. The process of claim 4 in which the enhancer substance comprises a synthetic macromolecular substance.

~~9. The process of claim 8 in which the macromolecular substance comprises an oligomeric or polymeric quaternary ammonium salt.~~

~~10. The process of claim 9 in which the quaternary ammonium salt is a poly(vinylaryl quaternary ammonium salt).~~

11. The process of claim 10 in which the poly(vinylaryl quaternary ammonium salt) is poly(vinylbenzyltrimethylammonium chloride).


12. The process of claim 10 in which the poly(vinylaryl quaternary ammonium salt) is poly[vinylbenzyl-(benzyltrimethylammonium chloride)].

13. The process of any one of the preceding claims in which the chemiluminescent chemical compound is a thermally, chemically, electrochemically or enzymatically cleavable 1,2-dioxetane, acridinium ester, lucigenin or luciferin.

~~14. The process of claim 13 in which the chemiluminescent chemical compound comprises a 1,2-dioxetane.~~

15. The process of claim 14 in which the 1,2-dioxetane is enzymatically cleavable.

16. The process of claim 15 in which the 1,2-dioxetane is a 3-(2'-spiroadamantane)-4-methoxy-(3"-phosphoryloxy)phenyl-1,2-dioxetane salt.



17. The process of any one of the preceeding claims carried out in the presence of an auxiliary fluorophore extraneous to the energy-emitting fluorophore produced by the decomposition of the chemiluminescent chemical compound and capable of accepting energy from said fluorophore to emit in turn detectable energy.

18. The process of claim 17 in which the auxiliary fluorophore is admixed with the chemiluminescent chemical compound and the enhancer substance.

19. The process of claim 17 in which the auxiliary fluorophore is bonded to the portion of the chemiluminescent compound that, upon decomposition, produces the energy-emitting fluorophore.

20. The process of any one of claims 17-19 in which the auxiliary fluorophore is a fluorescein.

21. The process of claim 17 in which the auxiliary fluorophore is bonded to the enhancer substance.

22. The process of claim 21 in which the auxiliary fluorophore is a derivatized fluorescein capable of establishing a covalent bond with the enhancer substance.

23. The process of any one of the preceding claims in which the process carried out is ~~a step in an immunoassay~~.

24. The process of any one of claims 1-22 in which the process carried out is ~~a nucleic acid probe assay~~.

25. An aqueous composition comprising a chemiluminescent chemical compound as defined in any one of the preceding claims, capable of decomposing to release electromagnetic energy detectable to determine the presence, concentration or structure of an analyte and an amount of a water soluble substance as defined in any one of the preceding claims, sufficient to enhance the intensity of the released detectable energy as compared to the intensity of the detectable energy released in the absence of the enhancer substance.

26. The composition of claim 25 which also contains an auxiliary fluorophore as defined in any one of claims 17-22, extraneous to the energy-emitting fluorophore produced by the decomposition of the chemiluminescent chemical compound and capable of accepting energy from said fluorophore to in turn emit detectable energy.